Hyperfine, Inc.
Business
Hyperfine, Inc. is a health technology company that develops and commercializes the Swoop® Portable MR Imaging® System, an AI-powered, portable ultra-low-field brain magnetic resonance imaging device. The Swoop® system is a FDA-cleared, bedside-deployable brain MRI scanner designed for critical care, emergency departments, and neurology office settings, offering diagnostic-quality imaging without ionizing radiation. The company operates through direct sales in the United States and through distributor partnerships in international markets including Europe, Asia, Middle East, Canada, and India.
Summary from 10-K filed 2026-03-18
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total sales | 14 | 13 | 11 | 7 | 1 | |
| Total cost of sales | 7 | 7 | 6 | 6 | 3 | |
| Gross profit | 7 | 6 | 5 | 907,000 | −1 | |
| Research and development | 17 | 22 | 22 | 28 | 26 | |
| General and administrative | 16 | 17 | 20 | 32 | 27 | |
| Sales and marketing | 10 | 9 | 10 | 14 | 10 | |
| Total operating expenses | 44 | 49 | 53 | 75 | 64 | |
| Loss from operations | −37 | −43 | −48 | −74 | −65 | |
| Interest income | 1 | 2 | 4 | 761,000 | 18,000 | |
| Change in fair value of warrant liabilities | 825,000 | 0 | — | — | — | |
| Other income (expense), net | −337,000 | 12,000 | 35,000 | −51,000 | −1,000 | |
| Loss before provision for income taxes | −36 | −41 | −44 | −73 | −65 | |
| Provision for income taxes | 0 | 0 | 0 | 0 | 0 | |
| Net loss and comprehensive loss | −36 | −41 | −44 | −44 | −65 | |
| Net loss per common share attributable to common stockholders, basic | −0.43 | −0.56 | −0.62 | −1.04 | −17.57 | |
| Net loss per common share attributable to common stockholders, diluted | −0.43 | −0.56 | −0.62 | −1.04 | −17.57 | |
| Weighted-average shares used to compute net loss per share attributable to common stockholders, basic | 82 | 72 | 71 | 70 | 4 | |
| Weighted-average shares used to compute net loss per share attributable to common stockholders, diluted | 82 | 72 | 71 | 70 | 4 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 35 | 38 | 75 | 117 | 188 | |
| Restricted cash | 957,000 | 28,000 | 621,000 | 771,000 | 3 | |
| Accounts receivable, less allowance of $1,372 and $651 in 2025 and 2024, respectively | 5 | 6 | 3 | 2 | 553,000 | |
| Unbilled receivables | 1 | 2 | 942,000 | 454,000 | 91,000 | |
| Inventory | 7 | 6 | 7 | 5 | 4 | |
| Prepaid expenses and other current assets | 1 | 2 | 2 | 3 | 1 | |
| Total current assets | 51 | 54 | 89 | 129 | 197 | |
| Property and equipment, net | 3 | 3 | 3 | 3 | 4 | |
| Other long term assets | 2 | 2 | 2 | 2 | 1 | |
| Total assets | 55 | 59 | 94 | 134 | 202 | |
| Accounts payable | 4 | 2 | 1 | 678,000 | 2 | |
| Deferred grant funding | 957,000 | 28,000 | 621,000 | 771,000 | 5 | |
| Deferred revenue | 2 | 1 | 1 | 1 | 730,000 | |
| Accrued expenses and other current liabilities | 5 | 6 | 5 | 6 | 8 | |
| Total current liabilities | 12 | 9 | 9 | 9 | 16 | |
| Warrant liabilities | 2 | 0 | — | — | — | |
| Long term deferred revenue | 729,000 | 1 | 968,000 | 2 | 510,000 | |
| Other noncurrent liabilities | 66,000 | 78,000 | 64,000 | — | — | |
| Total liabilities | 14 | 10 | 10 | 10 | 16 | |
| COMMITMENTS AND CONTINGENCIES (NOTE 13) | — | — | — | — | — | |
| Additional paid-in capital | 371 | 343 | 338 | 333 | 323 | |
| Accumulated deficit | −330 | −294 | −254 | −209 | −136 | |
| Total stockholders' equity | 41 | 49 | 84 | 124 | 186 | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 55 | 59 | 94 | 134 | 202 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −36 | −41 | −44 | −73 | −65 | |
| Depreciation | 1 | 1 | 1 | 1 | — | |
| Stock-based compensation expense | 3 | 4 | 5 | 11 | 7 | |
| Write-off of equipment | 121,000 | 215,000 | 224,000 | — | — | |
| Other | 27,000 | −11,000 | 25,000 | 91,000 | 85,000 | |
| Accounts receivable | 702,000 | −3 | −1 | −2 | −379,000 | |
| Unbilled receivables | 1 | −1 | −488,000 | −363,000 | −91,000 | |
| Inventory | −1 | 562,000 | −2 | −312,000 | −3 | |
| Prepaid expenses and other current assets | 436,000 | −222,000 | 1 | −2 | −666,000 | |
| Prepaid inventory | 0 | 693,000 | −412,000 | −281,000 | — | |
| Other long term assets | 240,000 | 325,000 | −220,000 | −632,000 | −1 | |
| Accounts payable | 2 | 382,000 | 533,000 | −2 | 1 | |
| Deferred grant funding | 929,000 | −593,000 | −123,000 | −2 | 1 | |
| Deferred revenue | −241,000 | 93,000 | −483,000 | 2 | 1 | |
| Due to related parties | −11,000 | 0 | 61,000 | −2 | 2 | |
| Accrued expenses and other current liabilities | 332,000 | −683,000 | −742,000 | −2 | 7 | |
| Operating lease liabilities, net | −8,000 | −5,000 | 10,000 | — | — | |
| Net cash used in operating activities | −28 | −39 | −42 | −72 | −47 | |
| Purchases of property and equipment | −1 | −383,000 | −804,000 | −585,000 | −3 | |
| Net cash used in investing activities | −1 | −383,000 | −804,000 | −585,000 | −3 | |
| Proceeds from exercise of stock options | 156,000 | 171,000 | 174,000 | 7,000 | 1 | |
| Proceeds from issuance of Class A common stock in connection with warrant exercises | 337,000 | 0 | — | — | — | |
| Net cash provided by financing activities | 28 | 1 | 174,000 | 7,000 | 177 | |
| Net decrease in cash and cash equivalents and restricted cash | −2 | −38 | −42 | −73 | 127 | |
| Noncash acquisition of property and equipment | 217,000 | 765,000 | — | — | — | |
| Unpaid purchase of property and equipment | 31,000 | 0 | 3,000 | — | — | |
| Initial measurement of warrant liabilities | 3 | 0 | — | — | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Hyperfine, Inc.'s CIK number?
Hyperfine, Inc.'s SEC CIK number is 0001833769 (1833769). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Hyperfine, Inc.'s SEC filings?
All of Hyperfine, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Hyperfine, Inc. last report earnings?
Hyperfine, Inc. (HYPR) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-219380). This is Hyperfine, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Hyperfine, Inc.'s most recent earnings 8-K?
Hyperfine, Inc.'s latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001193125-26-219380. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Hyperfine, Inc.'s latest earnings 8-K →
Look up any company's CIK number →